The Biotechnology Industry Organization (BIO), National Venture Capital Association, Pharmaceutical Research and Manufacturers of America, U.S. Chamber of Commerce, Delaware BioScience Association, Delaware State Chamber of Commerce and Delaware HIV Consortium organized the Delaware BioScience Business Roundtable held at Christiana Care’s John H. Ammon Medical Education Center on August 12.
This event brought together leaders from the bioscience, pharmaceutical, and chemical industries as well as top government officials.
The News Journal ran a great front page story on the event, here’s an excerpt:
The life sciences already have a strong footprint in Delaware, thanks in part to the presence of industry giants such as chemical and biotech firm DuPont Co., drug maker AstraZeneca and Agilent. A study earlier this year by the University of Delaware’s Center for Applied Demography & Survey Research found that the biopharmaceutical and related sectors employed nearly 12,000 people in Delaware in 2008.
Several speakers touted Delaware’s advantages in the field of life sciences, including its strong sense of community, easy access to government officials and high concentration of Ph.D.s.
“We have a lot to build on,” Gov. Jack Markell said in the event’s keynote speech.
The complete article and photos from the event can be seen by clicking here.
In addition to the newspaper coverage, some of us were offering live twitter updates – here’s a sample:
We were fortunate enough to catch up with some of the participants and get their insights on the BioScience Industry in Delaware, the U.S., and the world.
Gov. Jack Markell
Patrick Kelly, Vice President for State Government Relations and Alliance Development for the Biotechnology Industry Organization (BIO) based in Washington, DC
Catherine Bonuccelli, Global Product Vice President for Symbicort, AstraZeneca Pharmaceuticals LP